Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
AHA 2024 - Stephen Nicholls shares the findings of the phase 3 BROOKLYN study. “BROOKLYN shows us that we get many more patients with FH to treatment targets by adding the CETP inhibitor obicetrapib to their therapy”, says Stephen Nicholls.
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Gautam Nayak, MD
Michelle Kittleson, MD, PhD
Michelle Kittleson, MD, PhD
Frederick Ruberg, MD
